Literature DB >> 12842434

Gene transfer into genomes of human cells by the sleeping beauty transposon system.

Aron M Geurts1, Ying Yang, Karl J Clark, Geyi Liu, Zongbin Cui, Adam J Dupuy, Jason B Bell, David A Largaespada, Perry B Hackett.   

Abstract

The Sleeping Beauty (SB) transposon system, derived from teleost fish sequences, is extremely effective at delivering DNA to vertebrate genomes, including those of humans. We have examined several parameters of the SB system to improve it as a potential, nonviral vector for gene therapy. Our investigation centered on three features: the carrying capacity of the transposon for efficient integration into chromosomes of HeLa cells, the effects of overexpression of the SB transposase gene on transposition rates, and improvements in the activity of SB transposase to increase insertion rates of transgenes into cellular chromosomes. We found that SB transposons of about 6 kb retained 50% of the maximal efficiency of transposition, which is sufficient to deliver 70-80% of identified human cDNAs with appropriate transcriptional regulatory sequences. Overexpression inhibition studies revealed that there are optimal ratios of SB transposase to transposon for maximal rates of transposition, suggesting that conditions of delivery of the two-part transposon system are important for the best gene-transfer efficiencies. We further refined the SB transposase to incorporate several amino acid substitutions, the result of which led to an improved transposase called SB11. With SB11 we are able to achieve transposition rates that are about 100-fold above those achieved with plasmids that insert into chromosomes by random recombination. With the recently described improvements to the transposon itself, the SB system appears to be a potential gene-transfer tool for human gene therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842434     DOI: 10.1016/s1525-0016(03)00099-6

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  157 in total

1.  Enhancement of Sleeping Beauty transposition by CpG methylation: possible role of heterochromatin formation.

Authors:  Kosuke Yusa; Junji Takeda; Kyoji Horie
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

2.  Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells.

Authors:  Stephen R Yant; Julie Park; Yong Huang; Jacob Giehm Mikkelsen; Mark A Kay
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

3.  Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells.

Authors:  Xin Huang; Hongfeng Guo; Syam Tammana; Yong-Chul Jung; Emil Mellgren; Preetinder Bassi; Qing Cao; Zheng Jin Tu; Yeong C Kim; Stephen C Ekker; Xiaolin Wu; San Ming Wang; Xianzheng Zhou
Journal:  Mol Ther       Date:  2010-07-06       Impact factor: 11.454

4.  Herpes simplex virus/Sleeping Beauty vector-based embryonic gene transfer using the HSB5 mutant: loss of apparent transposition hyperactivity in vivo.

Authors:  Suresh de Silva; Michael A Mastrangelo; Louis T Lotta; Clark A Burris; Zsuzsanna Izsvák; Zoltán Ivics; William J Bowers
Journal:  Hum Gene Ther       Date:  2010-10-22       Impact factor: 5.695

Review 5.  CAR-T Cell Therapy for Lymphoma.

Authors:  Carlos A Ramos; Helen E Heslop; Malcolm K Brenner
Journal:  Annu Rev Med       Date:  2015-08-26       Impact factor: 13.739

Review 6.  Fishing for answers with transposons.

Authors:  Shannon A Wadman; Karl J Clark; Perry B Hackett
Journal:  Mar Biotechnol (NY)       Date:  2005-05-05       Impact factor: 3.619

Review 7.  A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.

Authors:  Harjeet Singh; Helen Huls; Partow Kebriaei; Laurence J N Cooper
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges.

Authors:  Michael A Goodman; Punam Malik
Journal:  Ther Adv Hematol       Date:  2016-06-25

Review 9.  CARs in chronic lymphocytic leukemia -- ready to drive.

Authors:  Chitra Hosing; Partow Kebriaei; William Wierda; Bipulendu Jena; Laurence J N Cooper; Elizabeth Shpall
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

10.  De novo induction of genetically engineered brain tumors in mice using plasmid DNA.

Authors:  Stephen M Wiesner; Stacy A Decker; Jon D Larson; Katya Ericson; Colleen Forster; Jose L Gallardo; Chunmei Long; Zachary L Demorest; Edward A Zamora; Walter C Low; Karen SantaCruz; David A Largaespada; John R Ohlfest
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.